Previous 10 | Next 10 |
Takeda’s Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency and showed clinically meaningful and significant effects in multiple key secondary efficacy endpoints all with p-values ≤ 0.008 Takeda’s Skyway st...
2024-05-28 13:09:08 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors should focus on these penny stocks to sell in May to avoid potential losses. While more affordable and often appealing to investors with limited capital, Penny stocks can also car...
2024-05-20 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips No matter what anyone says, the very concept of penny stocks to buy must be treated with extreme skepticism. I’m not talking about having an aggressive mistrust toward such enterpris...
2024-05-14 13:54:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ovid Therapeutics (NASDAQ: OVID ) just reported results for the first quarter of 2024. Ovid Therapeutics reported earnings per share of -17 cents. This was above the analy...
2024-05-14 10:32:00 ET More on Ovid Therapeutics Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024 Ovid Therapeutics gains on bullish view at Wedbush Seeking Alpha’s Quant Rating on Ovid Therapeutics Historical earnings data for...
Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are anticipated in Takeda's H1 2024 fiscal year A Phase 1, double-blind, multiple-ascending dose trial evaluating OV888 (GV101) is complete; topline sa...
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by rare epilepsies and brain conditions, today announced that management will par...
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
Commercial National Financial Corp. (CNAF) is expected to report for Q1 2024 First National Bank Alaska (FBAK) is expected to report for Q1 2024 Cyxtera Technologies Inc. (CYXTQ) is expected to report for quarter end 2024-03-31 Brookfield Renewable Corporation Class A Subordinate (BEP...
2024-04-09 10:48:41 ET Summary Ovid Therapeutics results from the phase 3 Skyline study, using soticlestat for the treatment of patients with Dravet Syndrome, expected by or before September of 2024. The global Dravet Syndrome market is expected to reach $1 billion by 2036. Re...
News, Short Squeeze, Breakout and More Instantly...
Ovid Therapeutics Inc. Company Name:
OVID Stock Symbol:
NASDAQ Market:
Ovid Therapeutics Inc. Website:
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB) Neuroscientists Dr. Ja...
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and pr...
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily d...